AzurRx BioPharma, Inc. AZRX
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 34.38M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.93
- Beta
- 1.51
- Short ratio
- 0.19
- Inst. own
- 5.82%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 15, 2021
- 50-d avg
- 4.94
- 200-d avg
- 7.50
- 1y target
- 16.00
Key statistics
- Market cap
- 34.38M
- Enterprise value
- 24.64M
- Trailing P/E
- 0.00
- Forward P/E
- -0.93
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.05
- EPS (TTM)
- -15.49
- Beta
- 1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -26.37M
- Total cash
- 8.07M
- Total debt
- 543.81K
- Return on equity
- -1271.87%
- Shares outstanding
- 9.97M
- Short % of float
- 0.17%
- 50-day average
- 4.94
- 200-day average
- 7.50
Analyst view
Consensus: buy
- Target (low)
- 8.00
- Target (mean)
- 16.00
- Target (high)
- 20.00
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 15, 2021
Expected Nov 15, 2021. Consensus EPS estimate -0.80.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2021 | Sep 1, 2021 | -0.79 | — | — | — |
| Aug 16, 2021 | Jun 1, 2021 | -0.80 | — | — | — |
| May 24, 2021 | Mar 1, 2021 | -0.70 | — | — | — |
| Mar 31, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
| Nov 16, 2020 | Sep 1, 2020 | -1.20 | — | — | — |
| Aug 14, 2020 | Jun 1, 2020 | -0.90 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 2, 2021 | HC Wainwright & Co. | main | — | Buy |
| Apr 1, 2021 | Roth Capital | main | — | Buy |
| Apr 1, 2021 | HC Wainwright & Co. | main | — | Buy |
| Feb 10, 2021 | HC Wainwright & Co. | main | — | Buy |
| Apr 1, 2020 | H.C. Wainwright | reit | — | Buy |
| Sep 26, 2019 | H.C. Wainwright | reit | — | Buy |
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- azurrx.com
News
- AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
- 3 Penny Stocks That Top Investors Buying Right Now
- 46 Biggest Movers From Yesterday
- AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
- 36 Stocks Moving In Tuesday's Mid-Day Session
- AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
- AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
- AzurRx BioPharma Announces Reverse Merger With First Wave Bio
- AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
- AzurRx BioPharma Announces Reverse Stock Split
Your note
Sign in to keep a note on AZRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORKOWSKI EDWARD J | Director | Stock Award(Grant) | Mar 9, 2020 | 423,453 |
| CASAMENTO CHARLES J | Director | Stock Gift | Mar 18, 2020 | 224,996 |
| DUPRET DANIEL | Officer | Stock Award(Grant) | Jul 11, 2018 | 15,000 |
| PELICAN PARTNERS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 29, 2017 | 1,727,800 |
| RIDDELL ALASTAIR | Director | Stock Award(Grant) | Mar 10, 2020 | 132,049 |
| ROSS EDMUND BURKE JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 30, 2018 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 0.31% | 292,409 | 2.40M | Jun 29, 2021 |
| Bank Of New York Mellon Corporation | 0.09% | 86,308 | 707.73K | Jun 29, 2021 |
| Geode Capital Management, LLC | 0.05% | 43,355 | 355.51K | Jun 29, 2021 |
| Renaissance Technologies, LLC | 0.02% | 17,323 | 142.05K | Jun 29, 2021 |
| Citadel Advisors LLC | 0.02% | 17,227 | 141.26K | Jun 29, 2021 |
| Parsons Capital Management, Inc. | 0.02% | 16,820 | 137.92K | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.23% | 210,413 | 1.73M | Jun 29, 2021 |
| Vanguard Extended Market Index Fund | 0.08% | 72,751 | 596.56K | Jun 29, 2021 |
| Fidelity Extended Market Index Fund | 0.03% | 30,693 | 166.91K | Jul 30, 2021 |
| Fidelity Series Total Market Index Fund | 0.01% | 6,734 | 36.62K | Jul 30, 2021 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.01% | 6,494 | 53.25K | Jun 29, 2021 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.01% | 6,092 | 33.13K | Jul 30, 2021 |